Biotech Pharma successfully completed the export delivery of monoclonal antibody bulk substance, overcoming challenges such as the pandemic.-BIOTECH PHARMACEUTICAL CO., LTD_EGF Vaccine

Home
About Us
About Us

BPL is a high-tech China-Cuba joint venture among first group engaged in the development, production and sales of monoclonal antibodies in China.
S&T
S&T

International-standard humanized monoclonal antibody preparation processes and large-scale, continuous mammalian cell culture technology.
- Research Areas
- Technology Platforms
Research and Development
Research and Development

China has developed nivolumab, a humanized monoclonal antibody drug (trade name: TaiXinSheng), for the treatment of malignant tumors.
Blog
Blog

Integrating industry-related media coverage as well as the company’s various activities and updates.
- Company News
- Media Reports
Join Us
Join Us

Boasting a postdoctoral research workstation and diverse career opportunities, we sincerely invite talented individuals from all fields to join Baite.
- Post-Doctoral Center
Contact Us
Contact Us

ThaiXinLife Consultation Hotline: +86 4006592330
Company Main Line: +86-10-51571020
- Contact Us

Biotech Pharma successfully completed the export delivery of monoclonal antibody bulk substance, overcoming challenges such as the pandemic.

Category:

Blog

Company News

Author:

Source:

Release date:

2022-05-27

Biotech Pharma overcame challenging conditions such as domestic and international pandemic disruptions, tight capacity on global air routes, and staff quarantine requirements. With the collaborative efforts of foreign experts, Cuba's Center for Molecular Immunology, and other relevant organizations, the company successfully completed a multi-day, multi-country journey to deliver the nivolumab bulk substance to the buyer, marking a significant milestone in its export operations. 2022 Sees a Strong Start to Exports.